Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Alembic Pharmaceuticals Ltd. has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s recent downgrade from a Hold to a Sell rating reflects deteriorating price action and weakening market sentiment, underscored by a 2.21% decline in the latest trading session and a broader negative trend across weekly and monthly technical parameters.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 22 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Alembic Pharmaceuticals Ltd. experienced a notable decline today, hitting an intraday low of Rs 728, reflecting a sharp price pressure of -7.23% as the stock underperformed its sector and broader market indices amid a broadly bearish market environment.

Alembic Pharmaceuticals Ltd. has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Despite mixed signals from key indicators such as MACD, RSI, and moving averages, the stock’s recent price action and volume patterns suggest a nuanced outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Alembic Pharmaceuticals Ltd. posted a consolidated net profit of ₹202.70 crores in Q4 FY26, marking a robust 52.44% quarter-on-quarter growth and 29.20% year-on-year expansion. However, this headline figure conceals a troubling operational reality—the company's profit surge was driven almost entirely by a tax reversal that resulted in a negative tax rate of 69.90%, whilst core business metrics deteriorated significantly. The stock currently trades at ₹784.70, down 29.17% from its 52-week high, reflecting investor concerns about the underlying business trajectory.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 April 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Alembic Pharmaceuticals Ltd. has experienced a nuanced shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook as of late November 2025. Despite a modest day gain of 1.51%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum tools. This analysis delves into the recent technical parameter changes, price momentum, and comparative market performance to provide investors with a comprehensive view of the stock’s current positioning.

The Sensex climbed 4.03% on 8 Apr 2026, yet Alembic Pharmaceuticals Ltd. outpaced the broader market with a robust 7.92% gain, reaching an intraday high of Rs 730.05. This 4.03-percentage-point outperformance signals a distinctly stock-specific rally rather than a mere market tailwind.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 April 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

A sharp decline of 4.72% today dragged Alembic Pharmaceuticals Ltd. to a fresh 52-week low of Rs 645.1, extending a downward trend that has seen the stock lose nearly 32% over the past year. This underperformance stands in stark contrast to the broader market, with the Sensex down just 5.56% over the same period.

Alembic Pharmaceuticals Ltd. has reached a new 52-week low, with its stock price falling to Rs.659.55 today. This marks a significant decline amid broader market fluctuations and ongoing sector pressures, reflecting a challenging period for the company within the Pharmaceuticals & Biotechnology industry.

Alembic Pharmaceuticals Ltd. has reached a new 52-week low of Rs.665.1 today, marking a significant decline in its stock price amid a series of consecutive falls and underperformance relative to its sector and benchmark indices.

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.